Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
СтатьяКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mierzwa Michelle, Rosen Benjamin, Suresh Krithika, Dinesh Arjun, Regan Sam, Brummel Collin, Wong Kakit, Casper Keith, Prince Mark, Malloy Kelly, Shuman Andrew, Chinn Steven, Cao Yue, Aryal Madhava, Heft-Neal Molly, Stucken Chaz, Buchakjian Marisa, Forner David, Yalamanchi Pratyusha, Swiecicki Paul, Lawrence Theodore S, Akhdar Rawan, Tewari Muneesh, Bhambhani Chandan, Walline Heather, Brenner J Chad, Shah Jennifer, Worden Francis
Аннотация
PURPOSE: We conducted a phase II multicenter clinical trial to test the hypothesis that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR).
PATIENTS AND METHODS: Patients with stage I/II p16+ oropharyngeal squamous cell carcinoma were planned to receive radiation 70 Gy in 35 fractions with concurrent weekly carboplatin and paclitaxel. All patients underwent FDG-PET at baseline and at radiation therapy (RT) fraction 10. Patients with ≥50% decrease from baseline to mid-treatment metabolic tumor volume had treatment deescalated to 54 Gy in 27 fractions. The primary endpoint was LRR. Plasma HPV ctDNA was evaluated weekly and in surveillance.
RESULTS: Of 84 evaluable patients, 43% met deescalation criteria. With a median follow-up of 37.8 months, 24-month LRR for the entire cohort was 7.8% [90% confidence interval (CI), 2.6%-12.6%], which was less than the 25% rate specified for assessing noninferiority, thereby meeting the primary endpoint. At 1 month after RT, the mean of multiple quality of life measures between the two groups was improved in the 54 Gy cohort, exceeding the minimal clinically important difference threshold. During CRT, week 1 percentage increase in ctDNA relative to baseline was significantly associated with worse loco-regional control (LRC; HR = 1.052 per 10 percentage point increase in ctDNA; 95% CI, 1.007-1.099; P = 0.023) and loco-regional progression-free survival (HR = 1.038; 95% CI, 1.002-1.076; P = 0.035).
CONCLUSIONS: FDG-PET-based RT dose personalization resulted in promising LRR outcomes in early-stage oropharynx cancer with improved short-term patient-reported outcomes. Furthermore, HPV ctDNA changes early in treatment may predict LRC.
PATIENTS AND METHODS: Patients with stage I/II p16+ oropharyngeal squamous cell carcinoma were planned to receive radiation 70 Gy in 35 fractions with concurrent weekly carboplatin and paclitaxel. All patients underwent FDG-PET at baseline and at radiation therapy (RT) fraction 10. Patients with ≥50% decrease from baseline to mid-treatment metabolic tumor volume had treatment deescalated to 54 Gy in 27 fractions. The primary endpoint was LRR. Plasma HPV ctDNA was evaluated weekly and in surveillance.
RESULTS: Of 84 evaluable patients, 43% met deescalation criteria. With a median follow-up of 37.8 months, 24-month LRR for the entire cohort was 7.8% [90% confidence interval (CI), 2.6%-12.6%], which was less than the 25% rate specified for assessing noninferiority, thereby meeting the primary endpoint. At 1 month after RT, the mean of multiple quality of life measures between the two groups was improved in the 54 Gy cohort, exceeding the minimal clinically important difference threshold. During CRT, week 1 percentage increase in ctDNA relative to baseline was significantly associated with worse loco-regional control (LRC; HR = 1.052 per 10 percentage point increase in ctDNA; 95% CI, 1.007-1.099; P = 0.023) and loco-regional progression-free survival (HR = 1.038; 95% CI, 1.002-1.076; P = 0.035).
CONCLUSIONS: FDG-PET-based RT dose personalization resulted in promising LRR outcomes in early-stage oropharynx cancer with improved short-term patient-reported outcomes. Furthermore, HPV ctDNA changes early in treatment may predict LRC.
Предметные рубрики MeSH
HumansMaleFemaleMiddle AgedAgedOropharyngeal NeoplasmsChemoradiotherapyPapillomavirus InfectionsFluorodeoxyglucose F18Positron-Emission TomographySquamous Cell Carcinoma of Head and NeckPaclitaxelPapillomaviridaeAdultNeoplasm Recurrence, LocalCarboplatinCirculating Tumor DNAHuman Papillomavirus Viruses